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cated in the tips of cellular processes. Reduced levels of AVP 
in supernatant culture medium of p.G96D and p.C98G trans-
fected cells in comparison to p.A159T and WT cells were 
found.  Conclusions: We conclude that the p.G96D and
p.C98G mutations cause adFNDI in the two reported fami-
lies. The sequence variant p.A159T does not seem to have 
disease-causing effects.  Copyright © 2009 S. Karger AG, Basel 
 Introduction 
 Autosomal dominant familial neurohypophyseal dia-
betes insipidus (adFNDI) is a rare disease caused by cen-
tral vasopressin deficiency and seems to be largely, if not 
completely, penetrant. Commonly, the disease becomes 
apparent in the first decade of life after a non-suspicious 
period during infancy. adFNDI typically presents with 
persistent thirst, polydipsia and polyuria due to a defi-
ciency of circulating arginine vasopressin (AVP)  [1] . AVP 
is usually synthesized by magnocellular neurons of the 
supraoptic and paraventricular nuclei of the hypothala-
mus  [1, 2] .
 Consistent with the clinical findings, AVP deficiency 
develops in the first months of life and shows a rapid pro-
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 Abstract 
 Background: Autosomal dominant familial neurohypophy-
seal diabetes insipidus (adFNDI) is a rare disease with symp-
toms of polydipsia, polyuria and dehydration caused by ar-
ginine vasopressin deficiency. Disease onset is within 
infancy or adolescence. A variety of disease-causing muta-
tions of the arginine vasopressin neurophysin II gene  (AVP) 
on chromosome 20p13 have been described.  Methods: Two 
Polish families with adFNDI were screened for mutations. 
Processing of wild-type (WT) and mutant AVP was moni-
tored using immunocytochemical methods in stably trans-
fected Neuro2A cells. AVP secretion into the cell culture su-
pernatant was investigated with an enzyme immunoassay. 
 Results: In the first family a heterozygous p.G96D mutation 
was identified. Some patients additionally carried a novel 
heterozygous mutation p.A159T. The second family present-
ed with a heterozygous mutation p.C98G. Confocal laser mi-
croscopy unveiled accumulation of p.G96D and p.C98G 
 prohormones in the cellular bodies, whereas WT and
p.A159T prohormones and/or processed products were lo-
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gression to a severe disease after infancy with failure to 
elicit enough AVP to achieve urine concentration even 
under intense stimulation  [1] . The arginine vasopressin-
neurophysin II  (AVP)  gene is located on human chromo-
some 20 (20p13)  [3] and consists of three exons encoding 
the AVP preprohormone. The preprohormone comprises 
a signal peptide, the AVP nonapeptide, neurophysin II 
(NPII) and a C-terminal glycopeptide copeptin  [1, 4] 
( fig. 1 a). After translocation of the newly synthesized pre-
prohormone (or preproprotein) into the lumen of the en-
doplasmatic reticulum (ER) where the signal peptide is 
cleaved, the thereby originated AVP prohormone con-
sisting of AVP, neurophysin II and glycopeptide folds into 
its final conformation and subsequently dimerizes. Neu-
rophysin II is a cysteine-rich protein that contains seven 
disulfide bonds between its 14 cysteine residues. In nor-
mal precursor processing, one additional disulfide bond 
is formed within the AVP domain, and the copeptin (gly-
copeptide) moiety becomes glycosylated  [5, 6] . Concomi-
tantly, the prohormone oligomerizes and is released into 
the  trans Golgi network. The AVP peptide binds in a 
‘pocket’ formed by neurophysin II which protects it from 
proteolytic degradation during the axonal transport of 
the secretory granule to the neurohypophysis where AVP 
is released as required  [1, 7] .
 Many hypotheses for the pathogenesis of adFNDI have 
been postulated. Rutishauser et al.  [8] and others  [1, 9] 
 suggested that mutant precursor hormones are retained 
by the ER protein quality machinery resulting in cyto-
toxic accumulation and aggregation of protein in the 
neurons. A second hypothesis is that the mutant AVP 
prohormone is degraded by the cytosolic proteolytic sys-
tem. This might be caused by deficient or insufficient 
function of mutant NPII molecules which are usually re-
sponsible for safe axonal transport and prevention of in-
tracellular AVP proteolysis  [1, 10, 11] .
 Some of the over 30 mutations reported in the neuro-
physin II-coding region are thought to be responsible for 
protein misfolding by disrupting the intrachain disulfide 
bonds within neurophysin II which are responsible for 
the correct folding and stability of the AVP prohormone. 
Other mutations in the neurophysin II-coding region are 
located in the AVP-binding site  [3, 12] . Several mutations 
affect the signal peptide and are proposed to disrupt sig-
nal protein processing  [3, 13–15] . Four mutations are re-
ported in the AVP-coding region itself  [9, 11, 16, 17] . One 
of these (p.Y21H) apparently disrupts AVP binding to a 
‘pocket’ formed by several residues in the amino-termi-
nal domain of neurophysin  [9] .
 Here we screened two Polish families suffering from 
adFNDI for mutations in the  AVP  gene. Using functional 
studies we demonstrate that the p.G96D and p.C98G mu-
tations result in impaired cellular trafficking.
 Subjects and Methods 
 Subjects 
 Eleven Polish individuals out of two families with a history of 
adFNDI have been studied. In family 1, blood samples were ob-
tained from 6 individuals suffering from adFNDI and from 1 
family member presenting no clinical signs of adFNDI ( fig. 2 ). In 
family 2, blood samples from 4 members were taken, 3 of them 
presenting with symptoms of adFNDI. Blood samples from all 
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 Fig. 1.  a Structural organization of the  AVP gene and the protein 
vasopressin precursor.  b Sequence chromatograms demonstrat-
ing the heterozygous mutations g.1884G 1 A (p.G96D) and 
g.2239G 1 A (p.A159T) found in family 1 and g.1889T 1 G (p.C98G) 
detected in family 2 (lower panel) and the corresponding normal 
sequence (upper panel). 
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family members were obtained after written informed consent. 
Clinical symptoms and laboratory findings are displayed in  ta-
ble 1 . The study was approved by the local ethical committee, 
Medical University of Silesia, Poland.
 PCR and Sequencing 
 Genomic DNA was purified from peripheral blood using the 
QIAamp DNA Mini Kit (Qiagen GmbH, Hilden, Germany). Two 
independent 20   l PCR reactions and three primer pairs in part 
previously published by Ito et al.  [18, 19] ( table 2 ) were used to 
amplify the entire AVP-NPII-coding region. Sequencing was per-
formed using BigDye Terminator v1.1 Cycle Sequencing Kit (Ap-
plied Biosystems, Darmstadt, Germany) and an ABI 3100 Genet-
ic Analyzer (Applied Biosystems). To exclude rare polymor-
phisms, sequencing of the coding regions of exons 2 and 3 was 
performed in 50 unrelated, healthy individuals for exon 2 and in 
100 unrelated healthy individuals for exon 3.
 Construction of Expression Vectors 
 A pBluescript SK+ plasmid containing a 592-bp human wild-
type (WT) cDNA fragment encoding the entire human AVP-
NPII precursor protein was graciously provided by Prof. D. Rich-
ter, Institute for Cellular Biochemistry and Clinical Neurobiolo-
gy, University of Hamburg (Germany). Complete AVP cDNA was 
excised from the pBluescript SK+ vector by cleavage with  HindIII 
and  XbaI (New England Biolabs, Frankfurt, Germany) and cloned 
into the multi cloning site of the pcDNA3 expression vector (In-
vitrogen, San Diego, Calif., USA).
 Three different pcDNA3-AVP vectors were produced. The 
NPII moiety mutations p.G96D and p.C98G and the glycopeptide 
mutation p.A159T were introduced by site directed mutagenesis 
using oligonucleotides for a two-step PCR synthesis of mutant 
DNA according to Higuchi et al.  [20] . The insert and ligation 
boundaries of all constructed vectors were sequenced to exclude 
PCR-derived nucleotide changes.
 Cell Culture and Transfection 
 Mouse neuroblastoma Neuro2A cells (DSMZ, German Col-
lection of Microorganisms and Cell Cultures, Braunschweig, Ger-
many) were cultured in DMEM, supplemented with 10% heat-in-
activated fetal calf serum (Gibco Life Technologies, Karlsruhe, 
Germany). The cells were maintained in a 5% CO 2 atmosphere at 
37 ° C.
 Transfections with pcDNA3-AVP-WT, –G96D, –A159T, and 
–C98G were performed using Fugene 6 (Roche Applied Science, 
Mannheim, Germany) according to the manufacturer’s instruc-
tions. Lines stably expressing the AVP-NPII cDNAs were selected 
using 0.4 mg/ml G418 (Geneticin, Gibco Invitrogen Corp.,
Karlsruhe, Germany) as previously described  [17] .
 Immunostaining and Microscopy 
 For immunostaining and confocal laser scanning microscopy, 
stably transfected Neuro2A cells were grown on slides for 24 h in 
culture medium and an additional 24 h in serum-free culture me-
dium. Cells were then fixed with 4% formaldehyde and immuno-
stained. We used a primary goat anti-human NPII antibody (R&D 
Systems, Abington, UK) and a secondary Alexa 546 donkey anti-
goat IgG antibody (Molecular Probes, Invitrogen GmbH, Karls-
ruhe, Germany). Images were acquired using a TCS SP2 confocal 
laser microscope (Leica, Mannheim, Germany).
 AVP Radioimmunoassay (RIA) 
 For measurement of AVP levels from cell culture superna-
tants, a double antibody RIA according to a modified method of 
Glick and Kagan  [21] was performed using vasopressin direct
RIA (Bühlmann Laboratories AG, Schönenbuch, Switzerland). 
Neuro2A cells stably expressing AVP-NPII were seeded in 6-well 
plates overnight and cultured for 24 h in serum-free culture me-
dium before collecting supernatants for AVP RIA. The cells of 
each well were harvested, lysed and protein levels were deter-
mined using DC Protein Assay (BioRad, Hercules, Calif., USA). 
AVP values were detected as pg/ml and converted in pg per mil-
ligram of total cell lysate protein per well.
 Magnetic Resonance Imaging (MRI) 
 One affected member of family 1 (No. 6,  fig. 2 ) was studied on 
a 0.5 T MRI (Philips, Gyroscan) and 2 affected members of fam-
ily 2 (No. 3 & 4,  fig. 2 ) were studied on a 1.5 T MRI (Siemens, 
Symphony). High-resolution images were obtained with 230  ! 
230 mm field of view, 3 mm slice thickness. Sagittal and coronal 
series were acquired pre- and postcontrast (gadolinium-DTPA) 
and without fat suppression. T 1 -weighted spin-echo sequences 
were used for detection of ‘bright spots’ representing neurovesi-
cles in the axons of AVP-secreting neurons in the posterior pitu-
itary gland  [8] .
XXXp.A159T
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XXXp.C98G
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XXXXXXp.G96D
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 Fig. 2. Pedigrees of families 1 and 2. The individuals marked with 
numbers are those who were available for mutation screening
of the  AVP  gene. Black and white symbols represent clinically 
 affected and unaffected individuals, respectively. In the table
the occurrence of the disease-causing mutations g.1884G 1 A 
(p.G96D) and g.1889T 1 G (p.C98G) and the rare polymorphism 
g.2239G 1 A (p.A159T) detected in different individuals of fami-
lies 1 and 2 are summarized. 
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 Results 
 Molecular Analyses 
 The entire AVP  gene has been investigated in all num-
bered family members ( fig. 2 ). In family 1 all affected in-
dividuals showed a G 1 A transition in exon 2 at nucleotide 
position 1884 (g.1884G 1 A) ( fig. 1 ) which was not present 
in the healthy family member ( fig. 2 ). This mutation maps 
to cDNA position 287 (c.287G 1 A) and predicts a replace-
ment of glycine by aspartic acid in position 96 of the ami-
no acid sequence of the prepro-AVP-NPII-precursor-pro-
tein (p.G96D) which is equivalent to amino acid 65 of 
NPII (NP65). An additional missense mutation in exon 3 
at nucleotide position 2239 (g.2239G 1 A) ( fig. 1 ) encoding 
for the glycopeptide has been identified in 3 of the family 
members with or without symptoms of adFNDI ( fig. 2 ). 
This mutation concerns cDNA position 475 (c.475G 1 A) 
and predicts a replacement of alanine by threonine in 
Table 1. Clinical symptoms and laboratory findings of investigated individuals including urine and serum osmolality, and serum elec-
trolytes
Individual
No.
Serum
osmolality
mosm/l
Urine
osmolality
mosm/l
DDAVP
therapy
(Minirin)
Serum 
sodium
mmol/l
Serum 
potassium
mmol/l
Serum
ADH
pg/ml
Fluid intake
per 24 h, l
Nycturia
times per 
night
Family 1
1 n.d. n.d. no 143 4.2 n.d. 4.5 4
2 n.d. n.d. no 147 4.8 n.d. 2 0
3 n.d. n.d. no 146 4.4 n.d. 15 4
4 n.d. n.d. no 143 4.0 n.d. 14 4–5
5 288 203 no 141 4.0 2.15 12 6
6 290 230 yes 139 4.5 1.31 5.25 4
7 293 277 no 140 3.9 4.12 1.1 0–1
Family 2
1 291 209 4 ! 0.1 mg/day 139.1 4.15 1.38 12 4
2 292 536 no 138 4.25 3.99 1 0
3 296 213 4 ! 0.1 mg/day 140.7 5.08 0.46 15 9
4 323 198 2 ! 0.1 mg/day 140.7 5.33 0.73 8–9 3–4
For all individuals, fluid intake and nycturia as clinical symptoms in adFNDI (autosomal dominant familial neurohypophyseal 
diabetes insipidus) are displayed.
DDAVP = Desmopressin; ADH = antidiuretic hormone, synonym to vasopressin; n.d. = no data available secondary to lacking 
compliance of the family members. AVP radioimmunoassays have been performed following standard protocols published elsewhere 
[21] (normal range: 0.60–6.70 pg/ml).
Direction Primer
Exon 1 Forward 5-TGGCGGCCGCGTCTCGCCTCCACGGGAACA-3
Reverse 5-GCTATGGCTGCCCTGAGATGGCCCACAGTG-3
Exon 2 Forward 5-TCGCTGCGTTCCCCTCCAACCCCTCGACTC-3
Reverse 5-GCCCCCCCCCAGGCCCGCCCCCGCCGCGCA-3
Exon 3 Forward 5-CCCAGGGCGCCCGTGCTCACACGTCCTCCCG-3
Reverse 5-CCTCTCTCCCCTTCCCTCTTCCCGCCAGAG-3
Primers for exons 1 and 3 have been previously reported [17, 18]. The primers for exon 
2 have been slightly modified to improve sequencing results.
Table 2. Primers used for DNA 
amplification by PCR
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amino acid position 159 of the preproprotein (p.A159T) 
that is equivalent to amino acid 34 of copeptin (CP34). In 
all affected members of family 2 we identified a transver-
sion T 1 G in exon 2 at nucleotide position 1889 (g.1889
T 1 G) which concerns cDNA position 292 (c.292T 1 G) 
and predicts a replacement of cysteine by glycine in amino 
acid position 98 of the preproprotein (p.C98G) which is 
equivalent to amino acid 67 of NPII (NP67) ( fig. 1 ,  2 ).
 Sequencing of exons 2 and 3 of the  AVP gene of 50 
(exon 2) and 100 (exon 3) unrelated healthy individuals 
showed no polymorphisms in the nucleotide positions 
mentioned above.
 Functional Studies 
 Immunostaining: Confocal Laser Scanning Micro-
scopic Analysis of the Intracellular Localization of Anti-
Neurophysin II-Reactive Proteins. In order to compare 
intracellular trafficking of WT and mutant AVP NPII 
prohormones and their processed products, the intra-
cellular localization of neurophysin II-reactive proteins 
were determined in stably transfected Neuro2A cells 
( fig. 3 ).
 In cells transfected with pcDNA3-AVP-WT or
pcDNA3-AVP-A159T, NPII was localized in the dendrit-
ic parts of the axons and in vesicular structures in the tips 
of the cellular processes which appear to colocalize with 
secretory granules.
 In cells transfected with pcDNA3-AVP-G96D or
pcDNA3-AVP-C98G, neurophysin II-reactive proteins 
retained in the cytoplasmatic areas of the cellular bodies 
and to some extent in the dendritic parts of the neuronal 
cells. No activity has been detected in the tips of the cel-
lular processes where the secretory granules are expected 
to be located.
 AVP Radioimmunoassay. In order to investigate 
whether mutations in the patients of families 1 and 2 are 
crucial for vasopressin expression and excretion, we ex-
amined AVP secretion of Neuro2A cells stably trans-
16.00 μm 20.00 μm
20.00 μm20.00 μm
a
b d
c
 Fig. 3. Cellular localization of NPII-reac-
tive proteins in stably transfected Neu-
ro2A cells expressing WT AVP ( a ) as well 
as the AVP-p.G96D ( b ), the AVP-p.A159T 
( c ), and the AVP-p.C98G mutant proteins 
( d ). Expressed neurophysin II-reactive 
proteins were detected by incubation with 
a goat anti-human neurophysin II anti-
body and an Alexa 546 donkey anti-goat 
IgG antibody.  a ,  c NPII in the cytoplasm of 
the cellular body and in the tips of cellular 
processes where secretory granules are lo-
cated. To some extent NPII is localized in 
the dendritic part of the axons on its way 
to the secretory granules at the tip of
the axon marked with white arrows ( ] ).
 b ,  d NPII in the cytoplasm of the cellular 
body. To some extent NPII is localized in 
the dendritic part of the axons ( f ). There is 
no accumulation of NPII in the tip of the 
axons, and NPII seems not to be stored in 
secretory granules. 
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fected with WT and mutant vasopressin cDNAs. AVP 
levels in the supernatant culture medium were detected 
by RIA and referred to the protein content of each well 
( fig. 4 ).
 The two missense mutations, p.G96D and p.C98G, 
expressed by Neuro2A cells result in significantly lower 
vasopressin levels in the supernatant cell medium than 
cells transfected with WT cDNA. The point mutation 
p.A159T which has been detected in some affected and 
unaffected individuals of family 1 does not seem to have 
an effect on vasopressin secretion out of the cell into the 
culture medium. Neuro2A cells have previously been 
reported secreting no vasopressin to the culture medi-
um  [6, 7, 16] .
 Magnetic Resonance Imaging. The characteristic high-
intensity signal known as ‘bright spot’ in T 1 -weighted im-
ages without fat suppression of the pituitary was absent 
in all examined and affected individuals of both families. 
In  figure 5 , magnetic resonance images of the pituitary 
gland of individual No. 6 (family 1) and individuals No. 
3 & 4 (family 2) are displayed in comparison to a non-re-
lated normal control.
 Discussion 
 Two heterozygous mutations in exon 2 of the  AVP 
gene encoding for neurophysin II (p.G96D and p.C98G) 
and one previously unidentified missense mutation in 
Family 1 Family 2
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0
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 Fig. 4. Effect of the point mutations p.G96D (g.1884G 1 A), p.C98G 
(g.1889T 1 G) and p.A159T (g.2239G 1 A) on vasopressin secretion 
of transfected cells into the cell culture medium. Absolute AVP 
values are displayed in boxes including standard deviations (SD). 
Relative values normalized to the cellular protein content of each 
well (in pg AVP per mg protein) are illustrated as boxplots con-
taining the median, upper and lower quantiles and upper and 
lower whisker intervals.  Fig. 5. MRI of affected family members in comparison to a non-
related control: ( a ) family 1, individual No. 6, ( b ) family 2, indi-
vidual No. 3, ( c ) family 2, individual No. 4, and ( d ) control indi-
vidual. In the pre-contrast T 1 -weighted sequences, no typical 
high-intensity signal in projection to the posterior pituitary gland 
could be displayed in all 3 patients. The hypophysis is projected 
in orthotopic location. An ectopic pituitary gland was not seen. 
Note the normal high-intensity signal of the posterior lobe of the 
pituitary gland in an unaffected control individual ( d ). 
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exon 3 encoding for the glycopeptide (p.A159T) have 
been identified in two Polish kindreds suffering from 
adFNDI. Whereas the two mutations in exon 2 have 
been previously reported in other adFNDI patients  [7, 
22] , the p.A159T mutation is novel but does not coseg-
regate with the disease in family 1. Individuals carrying 
both mutations p.G96D and p.A159T show symptoms of 
adFNDI (individuals 1 and 3,  fig. 2 ) but not the indi-
vidual carrying the nucleotide substitution p.A159T 
alone (individual 2,  fig. 2 ). Therefore, p.A159T seems to 
be a sequence variant and not a disease-causing muta-
tion.
 Using transfection and immunocytochemistry assays 
and measuring AVP secretion of transfected Neuro2A 
cells, we show for the first time that the mutations
p.G96D and p.C98G cause a failure in transport of the 
mutant AVP-neurophysin II proteins to the tips of the 
cellular processes where the secretory granules are locat-
ed. This results consecutively in a marked reduction of 
AVP secretion. The location of two mutations in exon 2, 
where a number of additional mutations have been re-
ported, suggests this region as a hot spot for mutations 
and being of importance for appropriate secretion of 
AVP.
 In mutation-positive cells, immunocytochemistry un-
veiled NPII-reactive protein accumulation in the perinu-
clear cytoplasm where the ER is located. Si-Hoe et al.  [23] 
assumed that misfolded proteins might be trapped in the 
ER which causes proteolytic degradation of the deranged 
ER with consecutive progressive cell loss associated with 
increasing clinical symptoms in the affected individuals. 
The presence of some NPII-reactive protein in the axonal 
part of neurons of mutation-positive cells carrying
p.G96D or p.C98G mutations could be due to an impaired 
axonal transport of abnormally configured prohormones 
which passed through the ER and the Golgi control ma-
chinery. During axonal transport these abnormal pro-
teins may then get degraded by proteolytic enzymes  [1] . 
On the other hand, the presence of NP II-reactive protein 
in the axonal part of these cells might also be due to its 
intraendoplasmatic location as ER can be located in the 
cellular processes of Neuro2A cells in which stained pro-
teins might be trapped in this case. Based on our findings 
it cannot clearly be distinguished between these two pos-
sibilities.
 The presence of minimal levels of AVP in the cell cul-
ture supernatants of cells transfected with the p.G96D 
and p.C98G mutant AVP can be either due to a remaining 
activity of these cells to secrete AVP into the medium, to 
cell degradation or to subcellular mRNA trafficking and 
local translation in dendrites as recently reported by 
Mohr and Richter  [24] .
 For the g.2239G 1 A (p.A159T) sequence variant in 
exon 3, no functional relevance could be observed when 
compared to cells transfected with WT AVP. This result 
is in accordance with the lack of cosegregation of this 
mutation in family 1 and the lack of clinical symptoms in 
the individual carrying the g.2239G 1 A (p.A159T) se-
quence variant alone. On the other hand, it was not de-
tected in 100 alleles of unrelated healthy individuals. We 
therefore conclude that the g.2239G 1 A (p.A159T) se-
quence variant is a rare polymorphism and exclude a 
pathogenetic relevance.
 Mutations in the NPII-coding region of the  AVP gene 
seem to cause an early disease onset  [2, 12] . Nevertheless, 
Repaske et al.  [15] reported of a pedigree carrying signal 
peptide mutations exhibiting a wide range in the age of 
onset. In family 1 there is lacking clinical information 
secondary to a persistent non-compliance. Serum AVP 
levels are in the lower range of normal in 2 of the 3 exam-
ined and affected family members. Individual No. 7 still 
has normal serum AVP levels but pathologic urine pa-
rameters (reduced osmolality) and a positive personal 
history with polydipsia and polyuria since 18 months of 
age. This might be due to persisting but diminishing neu-
rosecretory function of magnocellular neurons in the 
first years of life as already postulated by others, with pro-
gression to cytotoxic accumulation of mutant protein in 
the cytoplasmatic region of neurons  [1, 5, 8, 23] . Compar-
ing the limited clinical data of patients in family 1 carry-
ing the sequence variant g.2239G 1 A (p.A159T) in addi-
tion to the p.G96D point mutation, there seems to be no 
aggravating effect.
 Consistent with the results of Rutishauser et al.  [8] and 
others  [25–27] , all 3 investigated patients of the two fam-
ilies did not show the ‘bright spot’ in T 1 -weighted pitu-
itary images. Signal intensity is discussed to correlate 
closely with posterior lobe function as it is suspected to 
result from neurovesicles in axon endings of AVP-pro-
ducing neurons  [8, 28] . The absence of a ‘bright spot’ in 
the posterior pituitary lobe could therefore be the result 
of neurotoxic accumulation of precursor proteins  [1, 5, 8, 
23] leading to consecutive cell death  [19] .
 In family 1, individual No. 7 has been identified as be-
ing affected by genomic sequencing. At this time the 
child was 12 months old and asymptomatic. It was only 
at the age of 18 months that this child developed symp-
toms typical for adFNDI. This demonstrates the possibil-
ity of a preclinical diagnosis of adFNDI by genomic se-
quencing aiming at an early diagnosis and treatment of 
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